European Helicobacter and Microbiota Study Group

XXIXth International Workshop on Helicobacter & Microbiota in Inflammation & Cancer

Magdeburg, Germany
15–17 September 2016

Accepted Abstracts

Disclaimer
This abstract supplement has been produced using author-supplied copy. Editing has been restricted to some corrections of spelling and style where appropriate. No responsibility is assumed for any claims, instructions, methods or drug dosages contained in the abstracts; it is recommended that these are verified independently. This abstract book was correct at the time of printing and therefore does not reflect any programme changes after the date of printing.
The European Helicobacter and Microbiota Study Group

President
Peter Malfertheiner, Germany

Members
Leif P. Andersen, Denmark
Anthony Axon, United Kingdom
Lars Engstrand, Sweden
Bram Flahou, Belgium
Antonio Gasbarrini, Italy
Javier Gisbert, Spain
Ernst Kuipers, The Netherlands
Marcis Leja, Latvia
José C. Machado, Portugal
Francisco Mégraud, France
Colm A. O’Morain, Ireland
Ari P. Rämä, Finland
Theodore Rokkas, Greece

Emeritus Members
Michel A.L. Deltenre, Belgium
Giovanni Gasbarrini, Italy
Joseph A. Machado, Portugal
Colin A. O’Morain, Ireland
Avi P. Ristmäki, Finland
Theodore Rokkas, Greece

Elected Members
José M. Pajares García, Spain
Ashley B. Price, United Kingdom
Mario G. Quina, Portugal
Erik A.J. Roux, The Netherlands
Per Helge Sjöblom, Finland
Torkel M. Wadström, Sweden

Honorary Members
Franco Bazelli, Italy
James G. Fox, United States
David G. Graham, United States
Adrian Lee, Australia
Barry Marshall, Australia
Guido N.J. Tytgat, The Netherlands

Corresponding Fellows
Niyas Ahmed, India
Dmitriy Bordin, Russia
Luis G. Vaz Coelho, Brazil
Toshio Fujibayashi, Japan
Hyun Chae Jung, Korea
Varocha Mahachai, Thailand

Table of contents

Plenary Workshops
PW1 Plenary Workshop 1 71
PW2 Plenary Workshop 2 73
PW3 Plenary Workshop 3: Microbiota 74

Parallel Workshops
W1 Diagnosis, Epidemiology & Pediatrics 76
W2 Inflammation, Immunity, Vaccines, Host interaction 79
W3 Treatment & Drug Resistance 81
W4 Virulence Factors, Pathogenesis and Genomics 84
W5 Gastric Cancer and Carcinogenesis 86
W6 Helicobacters and Extragastric Diseases 89

Posters
P01 Diagnosis of Helicobacter infection 92
P02 Epidemiology 102
P03 Paediatrics 112
P04 Virulence factors and pathogenesis of Helicobacter infection 115
P05 Microbiology and genomics of Helicobacter 125
P06 Gastric cancer and cancerogenesis 126
P07 Treatment of Helicobacter infection 137
P08 Drug resistance and clinical issues 155
P09 Inflammation, immunity, vaccines and host interaction 160
P10 Helicobacter and extragastroduodenal disease 164
P11 Microbiota 1 168
P12 Microbiota 2 173

Author Index 178
Keyword Index 186
Aim: To investigate the relation between recurrent abdominal pain/discomfort and GL presence according to pain localization and frequency in adolescents.

Methods: 95 adolescents (aged 11–17, boys/girls ratio – 35/60), referred to a pediatric gastroenterology center (Krasnoyarsk, Siberia, Russia), were screened by Questionnaire on Pediatric Gastrointestinal Symptoms Rome III Version (QPGS-RIII) and tested to GL positivity by duodenal juice microscopy. No tested adolescents had chronic diarrhea, failure to thrive, immunodeficiency, erosions/ulcer according to upper endoscopy or celiac disease/inflammatory bowel disease. Pearson’s chi-squared test was used.

Results: No associations were detected between GL positivity and recurrent abdominal pain/discomfort absence/presence, localizations, and frequency (Table 1).

Conclusion: We suppose that GL chronic infection does not play causative role in recurrent abdominal pain in the majority of adolescents, although it may be possible in some clinical groups such as patients with immunodeficiency, chronic diarrhoea, malabsorption syndrome, and weight loss.

Table 1. GL positivity percentages in adolescents with different RAP localization and frequency

<table>
<thead>
<tr>
<th>QPGS-RIII QUESTIONS</th>
<th>Answers</th>
<th>1–3 times a month</th>
<th>Once a week</th>
<th>Several times a week or every day</th>
<th>p (Pearson Chi-square)</th>
</tr>
</thead>
<tbody>
<tr>
<td>In the last 2 months, how often did you have pain or an uncomfortable feeling in the upper abdomen above the belly button?</td>
<td>Never</td>
<td>(10/16)</td>
<td>(7/16)</td>
<td>(13/23)</td>
<td>(19/40)</td>
</tr>
<tr>
<td>In the last 2 months, how often did you have a belly ache or pain in the area around or below the belly button?</td>
<td>53%</td>
<td>(19/36)</td>
<td>50%</td>
<td>(16/32)</td>
<td>50%</td>
</tr>
</tbody>
</table>

Aim: To describe *H. pylori* infection features in a Portuguese paediatric gastroenterology reference centre over the last five years.

Methods: Review of upper digestive endoscopies reports performed in the context of gastric complaints with biopsies and *H. pylori* culture in a paediatric gastroenterology reference centre, between 2011 and 2015; selection of patients with full clinical and follow-up data for evaluation of eradication rate after antibiotic susceptibility testing-based treatment.

Results: In the studied period, a total of 1182 endoscopies with biopsies for *H. pylori* culture were performed in patients with gastric complaints; 512 (43.3%) children/adolescents (average age 11.9, range 2–17, 45.8% male) were positive. Full clinical and follow-up data was available for 216 patients. Among these, the most common gastric complaints were abdominal pain (78.7%) and vomiting (11.0%). At endoscopy, 86.1% of these children/adolescents presented with gastric nodularity; incidence of duodenal ulcer was 2.3%. Overall primary resistance rate was 36.7% for CH, 15.7% for MZ and 7.4% for CIP, with no significant time trends. For patients harbouring a CH-susceptible strain, eradication rate after triple therapy (PPI + AMX + CH, bid, 14 days), was 90.4%, while for patients harbouring a CH-resistant strain, eradication rate after triple therapy (PPI + AMX + MZ, bid, 14 days) was 89.3%.

Conclusion: These results show a high prevalence of *H. pylori* infection in the last years, as well high primary resistance rates to macrolides among Portuguese children, highlighting the importance of culture and antibiotic susceptibility testing for the correct managing of the infection in this age group.

**P03.03 | Helicobacter pylori Infection features in a paediatric gastroenterology reference centre in Portugal**

L. Oliveira*; A. Santos†; M. Oleastro‡; J. Cabral*
**Background:** Decreasing prevalence of *H. pylori* infection has been reported worldwide, in parallel with the improvement in sociodemographic conditions. In contrast, in Portugal, there is still a high prevalence of infection, including in pediatric population, and of gastric carcinoma.

**Aim:** This study aims to evaluate *H. pylori* prevalence, histological and antibiotic resistance patterns in symptomatic Portuguese children/adolescents attending a hospital in Lisbon.

**Methods:** Descriptive and retrospective study, with the review of diagnostic endoscopy records and gastric biopsies of 110 paediatric patients, between 2009 and June 2013.

**Results:** Globally, *H. pylori* infection rate was 51.8% (57/110), with the following distribution according to age: 54.9% (39/71) in children (≤12 years old) and 46.1% (18/39) in adolescents (13–17 years old). The mean annual prevalence was 30% in 2009, 37.5% in 2010, 47.1% in 2011, 58.1% in 2012 and 73.3% in 2013. Positive cases by histological evaluation revealed: chronic gastritis (96.5%), lymphoid aggregates (69.1%, *p* = 0.0008), acute inflammatory infiltrate (56.4%) and intestinal metaplasia (3.6%, *p* < 0.001). The intensity of the chronic inflammation was directly correlated with *H. pylori* infection; the majority of cases showed a moderate chronic inflammation (*p* = 0.0002). Antibiotic resistance was higher among adolescents for metronidazole (22.2% vs 18.2%) and ciprofloxacin (5.6% and 2.6%), while for clarithromycin it was higher among children (53.8% vs 44.4%).

**Conclusion:** The study highlights the clinical relevance of *H. pylori* infection in Portuguese paediatric patients, associated with high prevalence of infection, high resistance rate and relevant histological findings, pointing to a need of cost-effective management strategies.

**P03.05 | Helicobacter pylori and erosive-ulcer lesions in gastroduodenal tract in the children of Siberia**

N. G. Muravieva; T. V. Polivanova; V. A. Vshivkov

*Federal State Budgetary Scientific Institution 'Scientific Research Institute of Medical Problems of the North', Krasnoyarsk, Russian Federation*

**Aim:** To study the prevalence of erosive-ulcer lesions in mucosa of gastroduodenal area in the children of ethnic populations of Siberia and their associations with *H. pylori* infection.

**Materials and Methods:** Cohorts of children had been formed out of the schoolchildren by picking up by random (7–17 years) in Evenkia (Extreme North) and Tyva (South of Siberia). We performed gastroscopy followed by biopsy for those children. *H. pylori* was verified after Gimza coloring. In Evenkia we examined 83 Mongoloid children (the Evenks) and 80 Europeoids; in Tyva we examined 90 Mongoloids (the Tyvians) and 91 Europeoids.

**Results:** In Evenkia erosive-ulcer lesions were diagnosed in 13.3% of the Europeoids and 4.9% of the Evenks (*p* < 0.05); in Tyva in 19.8% of the Europeoids and 11.0% of the Tyvians correspondingly (*p* > 0.05). In Evenkia *H. pylori* was found in the Evenk children with destructive changes in 100% and in 83.5% of the children without mucosa defects; in the Europeoids in 93.8% and 71.6% correspondingly (*p* > 0.05). In Tyva in the Tyvians the same indices amounted to 69.2% and 64.9% correspondingly; in the Europeoids to 58.8% and 41.9% correspondingly, (*p* > 0.05). Nonetheless, in Tyva in the infected Europeoids we marked critical share of erosive duodenitis (14.6%), which was considerably higher than in the infected Tyvians (1.7%, *p* < 0.05).

**Conclusion:** In Siberia Mongoloids erosive-ulcer defects, including those associated with *H. pylori*, are determined less frequently in comparison with the Europeoids, which can be indicative of the more perfect protective mechanisms of a stomach in Siberia Mongoloids.

**P03.06 | Relationship between plasma ferritin level and upper recurrent abdominal pain frequency in adolescents depending on the helicobacter pylori infection status**

S. Tereshchenko*; N. Gorbacheva*; E. Anisimova†

*Medical Research Institute for Northern Problems, Russian Academy of Medical Sciences, Krasnoyarsk, Russian Federation*

†Krasnoyarsk State Medical University, Krasnoyarsk, Russian Federation

Many worldwide studies have shown robust relation between iron deficiency markers and chronic *Helicobacter pylori* (Hp) infection in adolescents. However, data regarding this relation often did not take into consideration the possible clinical signs of chronic Hp infection/iron deficiency such as recurrent abdominal pain (RAP) presence, localization and severity.

**Methods:** 80 adolescents with RAP complaints (aged 11–17), referred to a pediatric gastroenterology center (Krasnoyarsk, Russia), were screened by Questionnaire on Pediatric Gastrointestinal Symptoms Rome III Version (QPGS-RIII) and tested to Hp positivity (Hp antigen ELISA monoclonal test in stool, Immundiagnostik, Germany). No tested adolescents had erosions or ulcer according to upper endoscopy. Plasma concentrations of ferritin was estimated with ELISA kit (Beckman